ALDX (Aldeyra Therapeutics) Stock Based Compensation: $2.88 Mil (TTM As of Mar. 2026)


ALDX Aldeyra Therapeutics Inc ALDX
29 GF Score
Price $2.13
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics Stock Based Compensation?

Aldeyra Therapeutics ALDX +0.24% 29 Stock Based Compensation is $2.88 Mil as of Mar. 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Aldeyra Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $-0.99 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $2.88 Mil.

Aldeyra Therapeutics Stock Based Compensation Related Terms

Aldeyra Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics Stock Based Compensation Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.11 8.29 5.75 7.97 6.09

Aldeyra Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 0.20 2.58 1.09 -0.99
ALDX
29GF Score
Aldeyra Therapeutics Inc ALDX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.88 Mil.

What does a Stock Based Compensation of $2.88 Mil mean?
Aldeyra Therapeutics (ALDX) has a Stock Based Compensation of $2.88 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aldeyra Therapeutics and its competitors.
Is Aldeyra Therapeutics' Stock Based Compensation too high?
Aldeyra Therapeutics' current Stock Based Compensation is $2.88 Mil. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Stock Based Compensation compare to ONCY and VRCA?
Aldeyra Therapeutics' Stock Based Compensation of $2.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current Stock Based Compensation is $2.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current Stock Based Compensation of $2.88 Mil. The current Stock Based Compensation is $2.88 Mil. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current Stock Based Compensation is $2.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges 137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for ALDX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price